Live IPO - Expose Resources Ltd.

expose resources.png

Expose Resources (proposed ASX: EXX) is focused on exploring and developing high quality gold projects in Australia.

The flagship project is the Red Gate Gold Project located 10km north of Saracen Minerals’ (ASX: SAR) Porphyry Gold Mine in the prolific Eastern Goldfields of WA.

The Company has a fully approved 3,000m RC drill program planned to commence immediately on listing, designed to follow up and extend previous multiple intersections of broad, near-surface high-grade gold mineralization. The Project also hosts multiple other high priority targets which will be systematically drilled.

Recently EXX also effectively expanded Red Gate via an earn-in JV with GFI to earn up to 85% of the tenement adjacent to the East, importantly capturing an additional 3km strike length of the Reidys prospect.

The Company’s second project is the Roger River Gold Project in north-west Tasmania which represents an early stage epithermal-style project with large-scale discovery potential. A maiden drilling program at this target is also planned on listing.

The Company has assembled an experienced management, exploration and development team who are well qualified to exploit the potential of the Company’s mineral assets.

  • Pay by: March 22

  • List Price: $0.20

  • Minimum Investment: $2,000

  • Maximum Investment: No Limit.

  • Prospectus

Bid Now

Live IPO - Australian Industrial Minerals Ltd.

aim.png

Australian Industrial Minerals Ltd (ASX: AAM) ) has acquired 100% of Australian Abrasive Minerals Pty Ltd which holds the Harts Range Project, located 140km northeast of Alice Springs in the Northern Territory. The Project has JORC 2012 compliant Ore Reserves that support an initial mine life of 9.25 years, with Measured and Inferred Mineral Resources with potential to extend the mine life.  The Ore Reserves and Mineral Resources contain the complete range of garnet grain particle sizes required for industrial abrasive applications.

AAM’s objective is to extract, process and sell industrial abrasives (principally garnet) from an easily accessible alluvial sand deposit. These abrasives are used in abrasive blast cleaning, waterjet cutting and water filtration applications. The Company’s primary objective is to maximise production at the Project and leverage off the continued global demand for a reliable supplier of environmentally friendly abrasive products. The Company is also pursuing a strategy to become a diverse industrial minerals producer and supplier, by acquiring production-ready industrial mineral opportunities that are a strategic fit for the Company.

  • Pay by: March 8

  • List Price: $0.25

  • Minimum Investment: $2,000

  • Maximum Investment: $10,000

  • Prospectus

Bid Now

Live IPO - Koligo Therapeutics Ltd.

1527368198KoligoTherapeutics_logo.jpg

Koligo Therapeutics Ltd (ASX: KOL) was incorporated on 27 June 2018 for the primary purpose of acquiring Koligo Therapeutics, Inc (Koligo) a US biotechnology company focused on the development and commercialisation of a range of cell therapy, three-dimensional (3D) bioprinted tissue and other regenerative medicine products for serious unmet medical needs.

Koligo has successfully commercialised and has recently commenced selling its first cell therapy transplant product, Kyslecel™, for the treatment of chronic pancreatitis patients, in the United States.  Kyslecel™ is used in the treatment of patients suffering from chronic or acute recurrent pancreatitis, a debilitating and painful condition with few effective treatment options. Since 14 months ago, when sales commenced to a limited number of initial hospital customers, Koligo has generated revenues of approximately $1,600,000 from sales of this product.  

Koligo is currently developing Kyslecel™ v2.0, an improved formulation that is intended to extend the product’s shelf life and thus expand Koligo’s geographic reach. Koligo also seeks to develop and commercialize a range of other transformative cell therapies for a range of indications, including type 1 diabetes, and other pancreatic diseases; as well as 3D printed pre-vascularised cell/tissue structures for multiple indications, including liver failure, neurological diseases, metabolic disorders, and genetic disorders. Oversimplifying somewhat, pre-vascularised cell/tissue structures are 3D bio-printed for transplantation into humans with blood vessels already embedded in the tissue.

  • Pay by: March 22

  • List Price: $0.20

  • Minimum Investment: $2,000

  • Maximum Investment: $10,000

  • Prospectus

Bid Now

Live IPO - Mediland Pharm Ltd.

mediland pharm.jpg

Mediland Pharm Ltd (ASX: MPH) was founded as a Sydney based family business in 2002 and has grown to become a market leading retailer servicing the Chinese inbound tourism sector in Australia. With three strategically located retail outlets in Sydney, Melbourne and Surfers Paradise, the Company’s retail experience and merchandising strategies are designed to capture a significant share of the spending of the various tour groups.

By partnering with major travel agents and wholesale tour operators who are all Chinese Government certified under the Approved Destination Status (ADS) scheme, Mediland Pharm has grown strongly over the years, consistent with the growth of inbound tourist numbers from China and increasing level of expenditure by Chinese tourists.

  • Pay by: 11 February 19

  • List Price: $0.20

  • Minimum Investment: $2,000

  • Maximum Investment: $10,000

  • Prospectus

Closed

Live IPO - Irexchange Ltd

IREX_POS.CYAN_.png

irexchange Limited (ASX: IRX) is a disruptive technology platform and next-generation distribution business that aims to deliver fairness, transparency and efficiency to several traditionally wholesaler dominated industries including the fast-moving consumer goods (FMCG) industry.

To date, irexchange has raised in excess of $40 million to fund product and technology development, enhance market entry and support the rapid scaling up of its operations.

The platform and distribution model changes the relationship between retailers and suppliers by removing the costs of conventional wholesalers and providing price transparency to both retailers and suppliers across a wide range of popular stock keeping units (SKUs) in multiple segments in the grocery, frozen, produce and liquor sectors. 

  • Pay by: 05 February 19

  • List Price: $0.90

  • Minimum Investment: $2,001

  • Maximum Investment: $10,000

  • Prospectus

Closed